Cargando…

Management of Graves’ hyperthyroidism and orbitopathy in time of COVID-19 pandemic

Detalles Bibliográficos
Autores principales:	Bartalena, L., Chiovato, L., Marcocci, C., Vitti, P., Piantanida, E., Tanda, M. L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Opinion
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7241069/ https://www.ncbi.nlm.nih.gov/pubmed/32441005 http://dx.doi.org/10.1007/s40618-020-01293-7

Ejemplares similares

Effects of treatment modalities for Graves’ hyperthyroidism on Graves’ orbitopathy: a 2015 Italian Society of Endocrinology Consensus Statement
por: Bartalena, L., et al.
Publicado: (2015)

Epidemiology, Natural History, Risk Factors, and Prevention of Graves’ Orbitopathy
por: Bartalena, Luigi, et al.
Publicado: (2020)

Current concepts regarding Graves’ orbitopathy
por: Bartalena, Luigi, et al.
Publicado: (2022)

Graves’ disease and Graves’ orbitopathy following COVID-19
por: Lanzolla, G., et al.
Publicado: (2021)

Graves’ orbitopathy as a rare disease in Europe: a European Group on Graves’ Orbitopathy (EUGOGO) position statement
por: Perros, P., et al.
Publicado: (2017)

Antioxidant Therapy in Graves’ Orbitopathy
por: Lanzolla, Giulia, et al.
Publicado: (2020)

Role of teprotumumab in the treatment of active moderate-to-severe Graves’ orbitopathy
por: Bartalena, Luigi
Publicado: (2022)

Anti-nuclear autoantibodies in Graves’ disease and Graves’ orbitopathy
por: Lanzolla, G., et al.
Publicado: (2022)

Graves’ orbitopathy occurs sex-independently in an autoimmune hyperthyroid mouse model
por: Schlüter, Anke, et al.
Publicado: (2018)

Surgical complications in orbital decompression for Graves' orbitopathy
por: Sellari-Franceschini, S., et al.
Publicado: (2016)

Regulatory T Cells in the Pathogenesis of Graves’ Disease
por: Kustrimovic, Natasa, et al.
Publicado: (2023)

Selenium in the Treatment of Graves’ Hyperthyroidism and Eye Disease
por: Lanzolla, Giulia, et al.
Publicado: (2021)

Sirolimus as a second-line treatment for Graves’ orbitopathy
por: Lanzolla, G., et al.
Publicado: (2022)

Graves' Orbitopathy
por: Hiromatsu, Yuji, et al.
Publicado: (2015)

Immunological Drivers in Graves' Disease: NK Cells as a Master Switcher
por: Gallo, Daniela, et al.
Publicado: (2020)

Graves′ orbitopathy: Management of difficult cases
por: Wiersinga, Wilmar M.
Publicado: (2012)

Update on the surgical management of Graves’ orbitopathy
por: Baeg, Joonyoung, et al.
Publicado: (2023)

A Unique Presentation of Metastatic Follicular Thyroid Cancer Associated with Hyperthyroidism and an Active Graves’ Orbitopathy
por: Al-Jundi, Mohammad, et al.
Publicado: (2021)

Reasons for revision surgery after orbital decompression for Graves’ orbitopathy
por: Sellari-Franceschini, Stefano, et al.
Publicado: (2008)

Asymmetric Graves’ Orbitopathy
por: Panagiotou, Grigorios, et al.
Publicado: (2020)

Add-On Effect of Selenium and Vitamin D Combined Supplementation in Early Control of Graves’ Disease Hyperthyroidism During Methimazole Treatment
por: Gallo, Daniela, et al.
Publicado: (2022)

The Role of the Microbiota in Graves’ Disease and Graves’ Orbitopathy
por: Hou, Jueyu, et al.
Publicado: (2021)

Current Knowledge on Graves’ Orbitopathy
por: Gontarz-Nowak, Katarzyna, et al.
Publicado: (2020)

Orbital Signaling in Graves’ Orbitopathy
por: Draman, Mohd Shazli, et al.
Publicado: (2021)

Editorial: News in Graves’ orbitopathy: patients management and treatments
por: Lanzolla, Giulia, et al.
Publicado: (2023)

Endoscopic orbital decompression for Graves’ orbitopathy
por: Lal, Priti, et al.
Publicado: (2013)

Thyrotropin receptor antibodies and Graves’ orbitopathy
por: Diana, T., et al.
Publicado: (2020)

Significance of HLA in the development of Graves’ orbitopathy
por: Stasiak, Magdalena, et al.
Publicado: (2023)

Beneficial effect of low-dose radioiodine ablation for Graves’ orbitopathy: results of a retrospective study
por: Lanzolla, Giulia, et al.
Publicado: (2021)

Serum thyroglobulin is associated with orbitopathy in Graves’ disease
por: Khamisi, S., et al.
Publicado: (2021)

Planning health care for patients with Graves’ orbitopathy
por: Sasim, Inna V., et al.
Publicado: (2008)

Change in newly diagnosed Graves’ disease phenotype between the twentieth and the twenty-first centuries: meta-analysis and meta-regression
por: Ippolito, S., et al.
Publicado: (2020)

COVID-19: a cause of recurrent Graves’ hyperthyroidism?
por: Jiménez-Blanco, S., et al.
Publicado: (2020)

Thyroid Receptor Antibody and the Development of Graves’ Orbitopathy: Clinical Experience of using Radioiodine Ablation in the Management of Graves’ Orbitopathy in post-iodine ablation hypothyroid patient
por: Christina, Edelyn, et al.
Publicado: (2023)

Mechanisms That Underly T Cell Immunity in Graves’ Orbitopathy
por: Fang, Sijie, et al.
Publicado: (2021)

Correction to: Thyrotropin receptor antibodies and Graves’ orbitopathy
por: Diana, T., et al.
Publicado: (2021)

Roles of four targets in the pathogenesis of graves' orbitopathy
por: Ren, Ziqiang, et al.
Publicado: (2023)

Atypical Asymmetric Presentation of Severe Graves’ Orbitopathy
por: Gupta, Priyanka, et al.
Publicado: (2023)

Association between TSH-Receptor Autoimmunity, Hyperthyroidism, Goitre, and Orbitopathy in 208 Patients Included in the Remission Induction and Sustenance in Graves' Disease Study
por: Laurberg, Peter, et al.
Publicado: (2014)

Asymmetry indicates more severe and active disease in Graves’ orbitopathy: results from a prospective cross-sectional multicentre study
por: Perros, P., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_76b3akbgke2p2hgkf27e4u6j4b